#1 Clinical Trials Search in Europe

Tofacitinib Citrate

This article provides an in-depth look at the use of Tofacitinib Citrate in various clinical trials. Tofacitinib Citrate, also known by its brand name Xeljanz, is a medication that has been studied for its potential in treating a range of conditions, from autoimmune disorders to skin conditions. We’ll explore the different applications, dosage forms, and key findings from these trials to give you a comprehensive understanding of this drug’s potential in medical treatments.

Table of Contents

What is Tofacitinib?

Tofacitinib citrate, also known by the brand name Xeljanz, is a medication used to treat various inflammatory conditions[1]. It belongs to a class of drugs called Janus kinase (JAK) inhibitors, which work by reducing inflammation in the body[1]. Tofacitinib is an oral medication, meaning it is taken by mouth in the form of tablets or oral solution[2].

What Conditions Does Tofacitinib Treat?

Tofacitinib is used to treat several inflammatory conditions, including:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder that affects the joints, causing pain, stiffness, and swelling[3].
  • Psoriatic Arthritis (PsA): A type of inflammatory arthritis that affects some people with psoriasis, causing joint pain, stiffness, and swelling[4].
  • Ulcerative Colitis (UC): A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract[5].
  • Ankylosing Spondylitis (AS): A type of arthritis that primarily affects the spine, causing pain and stiffness in the back and other areas[1].
  • Juvenile Idiopathic Arthritis (JIA): A form of arthritis that affects children, causing joint pain, swelling, and stiffness[6].

How Does Tofacitinib Work?

Tofacitinib works by inhibiting certain enzymes in the body called Janus kinases (JAKs). These enzymes play a crucial role in the inflammatory process. By blocking JAKs, tofacitinib helps reduce inflammation and alleviate symptoms associated with various inflammatory conditions[1].

How is Tofacitinib Administered?

Tofacitinib is typically taken orally (by mouth) in the form of tablets. The dosage and frequency of administration may vary depending on the condition being treated and the individual patient’s needs. Some common dosing regimens include:

  • Tablets taken twice daily (BID)[4]
  • Once-daily extended-release tablets[5]
  • Weight-based dosing for children with JIA[6]

In some cases, tofacitinib may also be available as an oral solution, particularly for patients who have difficulty swallowing tablets or for children[2].

Effectiveness of Tofacitinib

Clinical trials have shown tofacitinib to be effective in treating various inflammatory conditions. Some key findings include:

  • Rheumatoid Arthritis: Tofacitinib has demonstrated improvements in joint pain, swelling, and overall disease activity in patients with RA[3].
  • Psoriatic Arthritis: Studies have shown that tofacitinib can improve joint symptoms, skin symptoms, and physical function in patients with PsA[4].
  • Ulcerative Colitis: Tofacitinib has been found to be effective in inducing and maintaining remission in patients with moderate to severe UC[5].
  • Ankylosing Spondylitis: Clinical trials have shown improvements in disease activity, physical function, and quality of life in patients with AS treated with tofacitinib[1].
  • Juvenile Idiopathic Arthritis: Tofacitinib has shown promise in improving symptoms and disease activity in children with JIA[6].

Potential Side Effects

Like all medications, tofacitinib can cause side effects. Some potential side effects observed in clinical trials include:

  • Increased risk of infections[1]
  • Changes in laboratory test results (e.g., blood cell counts, liver enzymes)[1]
  • Headache[1]
  • Gastrointestinal symptoms (e.g., diarrhea, nausea)[1]
  • Increased risk of certain cancers[1]
  • Cardiovascular events (e.g., blood clots)[1]

It’s important to discuss potential side effects and risks with your healthcare provider before starting tofacitinib treatment.

Ongoing Research

Researchers continue to study tofacitinib to better understand its effectiveness, safety, and potential new uses. Some areas of ongoing research include:

  • Long-term safety and efficacy in various conditions[6]
  • Use in pediatric populations[7]
  • Combination therapy with other medications[5]
  • Topical formulations for skin conditions[2]

As research continues, our understanding of tofacitinib and its potential benefits and risks may evolve. It’s important to stay informed and discuss any questions or concerns with your healthcare provider.

Condition Formulation Key Outcomes Measured Notable Findings
Juvenile Idiopathic Arthritis Oral tablets Safety, disease activity, joint function Long-term safety and efficacy being evaluated
Alopecia Areata Oral tablets Hair regrowth (SALT score), quality of life Potential for significant hair regrowth
Atopic Dermatitis Topical ointment Safety, lesion improvement (EASI score) Investigating efficacy of topical application
Dermatomyositis Oral tablets Disease improvement (IMACS DOI) Assessing effectiveness in treatment-resistant cases
Amyotrophic Lateral Sclerosis Oral tablets Safety, ALSFRS-R score changes Exploring potential neuroprotective effects

FAQ

  • What conditions is Tofacitinib Citrate being studied for? Tofacitinib Citrate is being studied for various conditions including juvenile idiopathic arthritis, alopecia areata, atopic dermatitis, dermatomyositis, and amyotrophic lateral sclerosis (ALS). It's also being tested in different formulations such as oral tablets and topical gels.
  • How is Tofacitinib Citrate administered in these trials? The administration of Tofacitinib Citrate varies depending on the study. It can be given as oral tablets, topical gels, or ointments. The dosage and frequency also vary based on the condition being treated and the specific trial design.
  • What are some of the primary outcomes being measured in these trials? Primary outcomes often include measures of drug safety and effectiveness. This can involve tracking adverse events, changes in disease activity scores, improvements in symptoms, and measurements of drug concentration in the blood (pharmacokinetics).
  • Are there any potential side effects of Tofacitinib Citrate mentioned in these trials? While specific side effects vary between trials, researchers are monitoring for adverse events such as infections, changes in blood cell counts, and cardiovascular events. Long-term safety is a key focus in many of these studies.
  • How long do these clinical trials typically last? The duration of the trials varies widely. Some are short-term studies lasting a few weeks, while others are long-term follow-up studies that can last for several months or even years. The length often depends on the condition being studied and the specific goals of the trial.

Ongoing Clinical Trials on Tofacitinib Citrate

  • Long-Term Study of Tofacitinib for Children and Teens with Juvenile Idiopathic Arthritis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland Spain

  • Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Finland France Germany Hungary Italy +4

Glossary

  • Tofacitinib Citrate: A medication that belongs to a class of drugs called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and so is able to have an active effect.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, a scale used to measure the functional status of ALS patients.
  • SALT score: Severity of Alopecia Tool score, used to measure the extent of hair loss in alopecia areata.
  • Juvenile Idiopathic Arthritis (JIA): A type of arthritis that affects children and teens, causing joint pain and inflammation.
  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin.
  • Dermatomyositis: A rare inflammatory disease characterized by muscle weakness and a distinctive skin rash.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being administered.

References

  1. https://clinicaltrials.gov/study/NCT03502616
  2. https://clinicaltrials.gov/study/NCT04468425
  3. https://clinicaltrials.gov/study/NCT04413617
  4. https://clinicaltrials.gov/study/NCT03486457
  5. https://clinicaltrials.gov/study/NCT06625450
  6. https://clinicaltrials.gov/study/NCT01500551
  7. https://clinicaltrials.gov/study/NCT04624230